Evaluating indeterminate interferon-γ-release assay results in patients with chronic inflammatory diseases receiving immunosuppressive therapy

Arthritis Care and Research

Volumn 67, Issue 8, 2015, Pages 1063-1069

  Calabrese, Cassandra ^a   Overman, Robert A ^a,b   Dusetzina, Stacie B ^b   Hajj Ali, Rula A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGE; ARTICLE; CHRONIC INFLAMMATORY DISEASE; COMORBIDITY; CONTROLLED STUDY; FEMALE; HEALTH SERVICE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY DISEASE; INTERFERON GAMMA RELEASE ASSAY; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS TEST KIT; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SPONDYLOARTHROPATHY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC VASCULITIS; AUTOIMMUNE DISEASES; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MIDDLE AGED; TUBERCULIN TEST; TUBERCULOSIS;

AUTOIMMUNE DISEASES; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA RELEASE TESTS; MALE; MIDDLE AGED; TUBERCULIN TEST; TUBERCULOSIS;

EID: 84937848086     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22454     Document Type: Article

References (27)

1. World Health Organization. WHO report 2011: global tuberculosis control. Geneva, Switzerland: World Health Organization; 2011. URL: http://www.who.int/tb/publications/global-report/2011/gtbr11-main.pdf.
2. Hamilton CD,. Tuberculosis in the cytokine era: what rheumatologists need to know [editorial]. Arthritis Rheum 2003; 48: 2085-91.
3. Furst DE, Cush J, Kaufmann S, Siegel J, Kurth R., Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biologic agents. Ann Rheum Dis 2002; 61 Suppl 2: ii62-3.
4. Wang L, Turner MO, Elwood RK, Schulzer M, FitzGerald JM., A meta-analysis of the effect of Bacille Calmette Guerin vaccination on the tuberculin skin test measurements. Thorax 2002; 57: 804-9.
5. Centers for Disease Control and Prevention. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection, United States-2010. MMWR Morb Mortal Wkly Rep 2010; 59: 1-25.
6. National Institute for Health and Clinical Excellence. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. 2011. URL: http://guidance.nice.org.uk/CG117/NICEGuidance/pdf/English.
7. Pai M, Zweling A, Mezies D,. Systematic review: T-cell based assays for the diagnosis of latent tuberculosis infection. An update. Ann Intern Med 2008; 148: 177-84.
8. Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, Gutierrez C, Cucho M, Alfaro J, et al., Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 2008; 35: 776-81.
9. Diel R, Loddenkemper R, Nienhaus A., Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. Chest 2010; 137: 952-68.
10. Belard E, Semb S, Ruhwald M, Werlinrud AM, Soborg B, Jensen FK, et al., Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis 2011; 17: 2340-9.
11. Kleinert S, Tony HP, Krueger K, Detert J, Mielke F, Rockwitz K, et al., Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-gamma release assays under real-life conditions. Ann Rheum Dis 2012; 71: 1791-5.
12. Mariette X, Baron G, Tubach F, Liote F, Combe B, Miceli-Richard C, et al., Influence of replacing tuberculin skin test with ex vivo interferon gamma release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy. Ann Rheum Dis 2012; 71: 1783-90.
13. Soborg B, Ruhwald M, Hetland ML, Jacobsen S, Andersen AB, Milman N, et al., Comparison of screening procedures for Mycobacterium tuberculosis infection among patients with inflammatory diseases. J Rheumatol 2009; 36: 1876-84.
14. QuantiFERON-TB Gold In-Tube [package insert]. Valencia (CA): Qiagen; 2013.
15. QuantiFERON-TB Gold technical notes. Indeterminate results. URL: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/medicaldevices/medicaldevicesadvisorycommittee/microbiologydevicespanel/ucm260551.pdf.
16. Kaelber DC, Foster W, Gilder J, Love TE, Jain AK., Patient characteristics associated with venous thromboembolic events: a cohort study using pooled electronic health record data. J Am Med Inform Assoc 2012; 19: 965-72.
17. Logical Observation Identifiers Names and Codes: User's Guide. 2014. URL: https://loinc.org/downloads/files/LOINCManual.pdf.
18. Spiegelman D., Easy SAS calculations for risk or prevalence rations and differences. Am J Epidemiol 2005; 162: 199-200.
19. Brunelli SM, Gagne JJ, Huybrechts KF, Wang SV, Patrick AR, Rothman KJ, et al., Estimation using all available covariate information versus a fixed look-back window for dichotomous covariates. Pharmacoepidemiol Drug Saf 2013; 22: 542-50.
20. Hsia EC, Schluger N, Cush JJ, Chaisson RE, Matteson EL, Xu S, et al., Interferon-gamma release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Arthritis Rheum 2012; 64: 2068-77.
21. Qumseya BJ, Ananthakrishnan AN, Skaros S, Bonner M, Issa M, Zadvornova Y, et al., QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. Inflamm Bowel Dis 2011; 17: 77-83.
22. Sauzullo I, Mengoni F, Scrivo R, Valesini G, Potenza C, Skroza N, et al., Evaluation of QuantiFERON-TB Gold In-Tube in human immunodeficiency virus infection and in patient candidates for anti-tumor necrosis factor-alpha treatment. Int J Tuberc Lung Dis 2010; 14: 834-40.
23. Vassilopoulos D, Tsikrika S, Hatzara C, Podia V, Kandili A, Stamoulis N, et al., Comparison of two interferon gamma release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy. Clin Vaccine Immunol 2011; 18: 2012-8.
24. Buttgereit F, Seibel MJ, Bijlsma JW., Glucocorticoids. In:, Rich R, Schroeder H, Fleisher T, et al, editors. Clinical immunology principles and practice. Philadelphia: Elsevier; 2008. p. 1293-305.
25. Kim EY, Lim JE, Jung JY, Young JS, Lee KJ, Yoon YW, et al., Performance of the tuberculin skin test and interferon-γ release assay for detection of tuberculosis infection in immunocompromised patients in a BCG-vaccinated population. BMC Infect Dis 2009; 9: 207.
26. Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A, Cucho M, Alfaro J, Perich R, et al., Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005; 64: 2360-1.
27. Cope AP., Studies of T-cell activation in chronic inflammation. Arthritis Res 2002; 4 Suppl 3: S197-211.